Lycorine inhibits Ang II-induced heart remodeling and inflammation by suppressing the PI3K-AKT/NF-κB pathway

  • Phytomedicine. 2024 Jun:128:155464. doi: 10.1016/j.phymed.2024.155464.
Pingping Tuo  1 Risheng Zhao  1 Ning Li  2 Shuang Yan  3 Gege Yang  1 Chunmei Wang  1 Jinghui Sun  1 Haiming Sun  4 Mengyang Wang  5
Affiliations
  • 1. Department of Pharmacology, College of Pharmacy, Beihua University, Jilin, Jilin, 132000, China.
  • 2. Department of Clinical Pharmacy, The First Hospital of Jilin University, Jilin, Changchun, 130012, China.
  • 3. Department of Ultrasonography, Inteqrated Traditional Chinese and Western Medicine Hospital of Jilin city Jilin Province, Jilin, 132000, China.
  • 4. Department of Pharmacology, College of Pharmacy, Beihua University, Jilin, Jilin, 132000, China. Electronic address: [email protected].
  • 5. Department of Pharmacology, College of Pharmacy, Beihua University, Jilin, Jilin, 132000, China. Electronic address: [email protected].
Abstract

Background: Ang II induces hypertensive heart failure (HF) via hemodynamic and non-hemodynamic actions. Lycorine (LYC) is an alkaloid derived from Lycoris bulbs, and it possesses anti-cardiovascular disease-related activities. Herein, we explored the potential LYC-mediated regulation of Ang II-induced HF.

Methods: Over 4 weeks, we established a hypertensive HF mouse model by infusing Ang II into C57BL/6 mice using a micro-osmotic pump. For the final two weeks, mice were administered LYC via intraperitoneal injection. The LYC signaling network was then deduced using RNA Sequencing.

Results: LYC administration strongly suppressed hypertrophy, myocardial fibrosis, and cardiac inflammation. As a result, it minimized heart dysfunction while causing no changes in blood pressure. The Nuclear Factor kappa B (NF-κB) network/phosphoinositol-3-kinase (PI3K)-protein kinase B (Akt) was found to be a major modulator of LYC-based cardioprotection using RNA Sequencing study. We further confirmed that in cultured cardiomyocytes and mouse hearts, LYC reduced the inflammatory response and downregulated the Ang II-induced PI3K-AKT/NF-κB network. Moreover, PI3K-AKT or NF-κB axis depletion in cardiomyocytes completely abrogated the anti-inflammatory activities of LYC.

Conclusion: Herein, we demonstrated that LYC safeguarded hearts in Ang II -stimulated mice by suppressing the PI3K-AKT/NF-κB-induced inflammatory responses. Given the evidence mentioned above, LYC is a robust therapeutic agent for hypertensive HF.

Keywords
AKT; Angiotensin II; Hypertensive heart failure; Lycorine; PI3K.
Products